Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Preethi Sankaran"'
Autor:
Shuming Chen, Tracee L. McMiller, Abha Soni, Farah Succaria, John-William Sidhom, Laura C. Cappelli, Livia A. Casciola-Rosen, Isaac R. Morales, Preethi Sankaran, Alan E. Berger, Julie Stein Deutsch, Qingfeng C. Zhu, Robert A. Anders, Jody E. Hooper, Drew M. Pardoll, Evan J. Lipson, Janis M. Taube, Suzanne L. Topalian
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Tumor regression following immune checkpoint blockade (ICB) is often associated with immune-related adverse events (irAEs), marked by inflammation in non-cancerous tissues. This study was undertaken to investigate the functional r
Externí odkaz:
https://doaj.org/article/44edc95deb6444eabbd3e50a4991237d
Autor:
Katherine E. Harris, Kyle J. Lorentsen, Harbani K. Malik-Chaudhry, Kaitlyn Loughlin, Harish Medlari Basappa, Sharon Hartstein, Ghenima Ahmil, Nicole S. Allen, Brian C. Avanzino, Aarti Balasubramani, Andrew A. Boudreau, Karen Chang, Maria-Cristina Cuturi, Laura M. Davison, Dennis M. Ho, Suhasini Iyer, Udaya S. Rangaswamy, Preethi Sankaran, Ute Schellenberger, Roland Buelow, Nathan D. Trinklein
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
Abstract The use of recombinant interleukin-2 (IL-2) as a therapeutic protein has been limited by significant toxicities despite its demonstrated ability to induce durable tumor-regression in cancer patients. The adverse events and limited efficacy o
Externí odkaz:
https://doaj.org/article/6280e71ffa694c31a509b1afcf87bff2
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/adebaadee24548908eaad0fc54ce187e
Autor:
Lawrence Fong, Serena Kwek, Rong Deng, Yuping Li, Kevin Dang, Giulia Castello, Starlynn C Clarke, Aarti Balasubramani, Andrew Boudreau, Laura Davison, Katherine E Harris, Duy Pham, Preethi Sankaran, Harshad S Ugamraj, Alec Starzinski, Suhasini Iyer, Wim van Schooten, Ute Schellenberger, Wenchao Sun, Nathan D Trinklein, Roland Buelow, Ben Buelow, Pranjali Dalvi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background Therapeutic options currently available for metastatic castration-resistant prostate cancer (mCRPC) do not extend median overall survival >6 months. Therefore, the development of novel and effective therapies for mCRPC represents an urgent
Externí odkaz:
https://doaj.org/article/b008929f34b84d778350eb4e4a7bcce4
Autor:
Starlynn C. Clarke, Biao Ma, Nathan D. Trinklein, Ute Schellenberger, Michael J. Osborn, Laure-Hélène Ouisse, Andrew Boudreau, Laura M. Davison, Katherine E. Harris, Harshad S. Ugamraj, Aarti Balasubramani, Kevin H. Dang, Brett Jorgensen, Heather Anne N. Ogana, Duy T. Pham, Payal P. Pratap, Preethi Sankaran, Ignacio Anegon, Wim C. van Schooten, Marianne Brüggemann, Roland Buelow, Shelley Force Aldred
Publikováno v:
Frontiers in Immunology, Vol 9 (2019)
Heavy chain-only antibodies (HCAbs) do not associate with light chains and their VH regions are functional as single domains, forming the smallest active antibody fragment. These VH regions are ideal building blocks for a variety of antibody-based bi
Externí odkaz:
https://doaj.org/article/6a706cdfcb4649ab82279f4b31c5c13b
Autor:
Victoria Jeffers, Edwin T. Kamau, Ananth R. Srinivasan, Jonathan Harper, Preethi Sankaran, Sarah E. Post, Joseph M. Varberg, William J. Sullivan, Jon P. Boyle
Publikováno v:
mSphere, Vol 2, Iss 1 (2017)
ABSTRACT New drugs to control infection with the protozoan parasite Toxoplasma gondii are needed as current treatments exert toxic side effects on patients. Approaches to develop novel compounds for drug development include screening of compound libr
Externí odkaz:
https://doaj.org/article/b3da351a960c48d3b9fbeae40b5dad3a
Autor:
Suhasini Iyer, Kaitlyn Loughlin, Andrew Boudreau, Dennis M. Ho, Laura Davison, Preethi Sankaran, Udaya Rangaswamy, Sharon Hartstein, Nicole S. Allen, Brian Avanzino, Harbani Kaur Malik-Chaudhry, Aarti Balasubramani, Ute Schellenberger, Karen Chang, Roland Buelow, Maria-Cristina Cuturi, Nathan D. Trinklein, Harish Medlari Basappa, Ghenima Ahmil, Kyle J. Lorentsen, Katherine E. Harris
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
The use of recombinant interleukin-2 (IL-2) as a therapeutic protein has been limited by significant toxicities despite its demonstrated ability to induce durable tumor-regression in cancer patients. The adverse events and limited efficacy of IL-2 tr
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundWe previously found upregulation of the cyclooxygenase-2/prostaglandin E2 (COX-2/PGE2) pathway in the tumor microenvironment (TME) of cancers that respond poorly to anti-PD-1 therapy.1–2 The potential functional role of this pathway in an
Autor:
Laura Davison, Suhasini Iyer, Roland Buelow, Rong Deng, Alec Starzinski, Wenchao Sun, Preethi Sankaran, Serena S. Kwek, Starlynn Clarke, Yuping Li, Nathan D. Trinklein, Lawrence Fong, Aarti Balasubramani, Pranjali Dalvi, Ute Schellenberger, Ben Buelow, Wim Van Schooten, Giulia Castello, Duy Pham, Andrew Boudreau, Harshad Ugamraj, Katherine E. Harris, Kevin Dang
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
BackgroundTherapeutic options currently available for metastatic castration-resistant prostate cancer (mCRPC) do not extend median overall survival >6 months. Therefore, the development of novel and effective therapies for mCRPC represents an urgent
Autor:
Katherine E. Harris, Suhasini Iyer, Starlynn Clarke, Pranjali Dalvi, Duy Pham, Yuping Li, Alexander Cheung, Lawrence Fong, Preethi Sankaran, Chiara Rancan, Ben Buelow, Kevin Dang, Laura Davison, Aarti Balasubramani, Alec Starzinski
Publikováno v:
Journal of Clinical Oncology. 38:e17583-e17583
e17583 Background: Castration resistant prostate cancer (CRPC) is an incurable disease and represents a significant unmet need. Prostate specific membrane antigen (PSMA) is a protein highly expressed on the surface of prostate cancer cells; expressio